Abstract:Abstract Introduction Recent transcriptome analysis developed a holistic tumor microenvironment (TME) classification platform based on immune and fibrotic markers. This TME classification had four categories, immune enriched, fibrotic (IE/F); immune enriched, non-fibrotic (IE); Fibrotic (F); and Immune Desert (D). And these four TME subtypes are a predictive biomarker to immunotherapy in multiple cancer and four subtypes have been changed during treatment. Previously our study suggested baseline immune features and dynamic immune response on-treatment were predictive of treatment outcome in BC with neoadjuvant chemotherapy (NAC). In this study, we evaluated the impact of TME classification and dynamic change of TME classification on treatment outcome in BC with NAC. Methods Early and locally advanced BCs which would be planned to receive standard NAC (four cycles of anthracycline plus cyclophosphamide and four cycles of docetaxel or docetaxel plus trastuzumab for human epidermal growth factor receptor 2[HER2+] disease or six cycles of docetaxel, carboplatin, trastuzumab and pertuzumab for HER2+ disease) followed by curative surgery. We prospectively collected tumor tissue and matched blood three times for each patients: at BC diagnosis (T1), three weeks after the first cycle of NAC (T2), and curative surgery (T3). RNASeq was performed to classify TME subtype. In terms of clinical variables, clinical stage and IHC subtype at diagnosis, pathologic complete response (pCR), distant recurrence free survival (DRFS) and overall survival (OS) were used. Generalized logistic regression was used for predicting RCB class and pCR with clinical and genomic characteristics at T1. Kaplan-Meier analysis were performed to analysis DRFS and OS. Results In total, 210 patients who were treated with scheduled NAC were enrolled. Finally, RNASeq in 240 BC tissues (T1:119, T2:91 and T3:30) were conducted from 142 patients. In 119 BCs which was performed RNASeq at T1, hormone receptor(HR)+, HER2- BC was 32 (26.9%), 29 of HR+HER2+ BC (24.4%), 18 of HR-HER2+ BC (15.1%) and 44 of triple negative BC (TNBC) (37.0%). In TME classification, immune desert (D) was most frequently observed (45.3%), followed by IE (35.3%), F (10.1%) and IE/F (9.2%). The association between BC subtype and TME subtype suggested that HR+HER2- BC was frequently categorized into D (22 of 32, 68.8%) whereas TNBC was into IE (24 of 44, 54.5%) (p< 0.001). TME subtype has been dynamically changed during NAC. At T2, IE subtype was most frequently observed (27.5%) followed by D (25.3%), IE/F (24.2%) and F (23.1%). The inclination of TME change were different according to NAC response. In BC achieved pCR, IE/F subtype had increased (4 at T1 and 10 at T2) and decrease of D subtype (15 at T1 and 3 at T2). In BC with non-pCR, IE/F subtype had slightly increased at T2 (7 at T1 and 12 at T2) but there was no IE/F subtype at T3 point. Contrarily, D subtype had decreased at T2 but increased at T3 (39 at T1, 20 at T2 and 24 at T3). The impact of TME subtype was different according to pCR status. In BC with pCR, F subtype had poor prognosis in DRFS and OS compared to other subtype ([5year DRFS rate for F vs. others: 66.7% vs. 93.2%, p=0.028], [5year OS rate for F vs. others: 70.7% vs. 100%, p< 0.001]). In BC without pCR, there was no different DRFS and OS according to TME subtypes. Conclusion Our data suggested that TME subtype has been changed during NAC and the subtype switching was affected by the NAC response. Moreover, TME subtype may have prognostic role in DRFS and OS according to pCR status. Citation Format: ji-Yeon Kim, Kyunghee Park, woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Yeon Hee Park. Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-01-37.

Abstract 6133: Intratumoral budding in pretreatment biopsies can predict prognosis and neoadjuvant therapy response among the tumor microenvironmental components in colorectal adenocarcinoma

Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma

Abstract 6434: Microenvironment of adjacent non-neoplastic regions determines prognostic outcomes in locally advanced colorectal cancer after surgical resection: A multi-center & multi-omics study

Are the tumor microenvironment characteristics of pretreatment biopsy specimens of colorectal cancer really effectively predict the efficacy of neoadjuvant therapy: A retrospective multicenter study

Abstract PO4-03-05: Prognostic value of Ki67 expression in post-treatment tumors of patients with residual triple-negative breast cancer after neoadjuvant chemotherapy

Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma

Abstract 2582: Intra- and peri-tumoral radiomic features are predictive of pathologic response to multiple neoadjuvant therapy regimen in rectal cancers via pre-treatment MRI

Differential effect of tumor budding on the benefit of adjuvant chemotherapy in stage II colorectal cancer: a retrospective observational study

Abstract 5269: Imaging the tumor microenvironment in rectal cancer: Decline in tumor blood flow (BF) during neoadjuvant treatment predicts excellent outcome

High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer

Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer

Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy

Abstract 1172: Association between CD8+ PD-1+ T cell infiltration levels and improved response to total neoadjuvant therapy in mismatch-repair proficient locally advanced rectal cancer

Abstract 6467: Tumor Mutation Burden Combined with Tumor Markers As Predictive Prognostic Biomarkers for Neoadjuvant Chemotherapy in Patients with Gastric Cancer

Abstract 7644: Prognostication of genomic characteristics of residual breast cancer after neoadjuvant chemotherapy

Abstract P6-01-37: Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer

Abstract 6186: Protein Panel for Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer Based on Proteomics

Abstract 1149: Spatial transcriptomic analysis of tumor microenvironment in patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy with immune checkpoint inhibitor

Abstract PS4-11: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Neoadjuvant Chemotherapy in Patients of Breast Cancer

Radiopathomics strategy combining multiparametric MRI with whole-slide image for pretreatment prediction of tumor regression grade to neoadjuvant chemoradiotherapy in rectal cancer

Abstract 7607: Single-cell genomics study before and after neoadjuvant therapy for triple-negative breast cancer